Mechanism of antibody reduction in cell culture production processes.

Biotechnol Bioeng

Protein Analytical Chemistry, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.

Published: November 2010

AI Article Synopsis

  • A significant issue with disulfide bond reduction in therapeutic antibody manufacturing was discovered during scale-up using a CHO expression system, particularly during harvest operations and protein A chromatography.
  • An excessive amount of mechanical cell lysis at the harvest step appears to contribute to the reduction of the antibody, resulting in the formation of fragments (light and heavy chains) in the product pools.
  • The mechanism behind this reduction seems to involve a thioredoxin system or similar reducing enzymes released into the harvest fluid, which can persistently reduce the antibody bonds, highlighting the need for improved manufacturing strategies to mitigate this problem.

Article Abstract

We recently observed a significant disulfide reduction problem during the scale-up of a manufacturing process for a therapeutic antibody using a CHO expression system. Under certain conditions, extensive reduction of inter-chain disulfide bonds of an antibody produced by CHO cell culture may occur during the harvest operations and/or the protein A chromatography step, resulting in the observation of antibody fragments (light chain, heavy chain, and various combination of both) in the protein A pools. Although all conditions leading to disulfide reduction have not been completely identified, an excessive amount of mechanical cell lysis generated at the harvest step appears to be an important requirement for antibody reduction (Trexler-Schmidt et al., 2010). We have been able to determine the mechanism by which the antibody is reduced despite the fact that not all requirements for antibody reduction were identified. Here we present data strongly suggesting that the antibody reduction was caused by a thioredoxin system or other reducing enzymes with thioredoxin-like activity. The intracellular reducing enzymes and their substrates/cofactors apparently were released into the harvest cell culture fluid (HCCF) when cells were exposed to mechanical cell shear during harvest operations. Surprisingly, the reducing activity in the HCCF can last for a long period of time, causing the reduction of inter-chain disulfide bonds in an antibody. Our findings provide a basis for designing methods to prevent the antibody reduction during the manufacturing process.

Download full-text PDF

Source
http://dx.doi.org/10.1002/bit.22848DOI Listing

Publication Analysis

Top Keywords

antibody reduction
20
cell culture
12
reduction
9
antibody
9
mechanism antibody
8
disulfide reduction
8
manufacturing process
8
reduction inter-chain
8
inter-chain disulfide
8
disulfide bonds
8

Similar Publications

Background: Since 2012, the northeast region of Tunisia has witnessed an increase in dog rabies cases, indicating a concerning emergence of the disease. Previous studies have indicated the widespread nature of rabies in northern Tunisia. However, there remains a lack of comprehensive understanding regarding the associated risk factors.

View Article and Find Full Text PDF

Highly pathogenic avian influenza (HPAI) is a viral disease caused by some H5 and H7 subtypes of influenza virus type A in most species of birds, especially poultry. HPAI viruses are among the most challenging viruses that threaten both human and animal health. Consequently, various strategies, such as the use of vaccines have been proposed to control the disease.

View Article and Find Full Text PDF

Eculizumab in thymoma-associated myasthenia gravis: a real-world cohort study.

Ther Adv Neurol Disord

December 2024

Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, No.12 Urumqi Middle Road, Jing 'an District, Shanghai 200040, China.

Background: Thymoma-associated myasthenia gravis (TAMG) is a subtype of myasthenia gravis (MG) that is associated with more severe symptoms and a relatively poor prognosis. Eculizumab, an inhibitor to target human C5 component of the complement cascade, is considered a treatment option for refractory generalized MG (gMG).

Objectives: To explore the safety and efficacy of eculizumab in patients with TAMG.

View Article and Find Full Text PDF

First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report.

Ther Adv Neurol Disord

December 2024

Department of Neurology, Faculty of Medicine, University of Augsburg, Stenglinstrasse 2, Augsburg 86156, Germany.

In acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), neonatal Fc-receptor (FcRn) inhibition has broadened the therapeutic spectrum. Myasthenic crisis (MC), heralded by an impending myasthenic crisis (iMC), is a critical condition requiring treatments with rapid onset and sustained efficacy. Currently treatments used for iMC, including intravenous immunoglobulins and plasma exchange/immunoadsorption, have limitations, such as delayed onset of action and potential side effects.

View Article and Find Full Text PDF

Purpose: Although studies have evaluated benralizumab, a monoclonal IL-5 receptor α antibody in severe eosinophilic asthma (SEA), in real-world settings, additional evidence is needed to further characterize its effectiveness in specific patient populations. Our study aimed to evaluate asthma control over 56 weeks in patients treated with benralizumab in Swiss real-world settings.

Patients And Methods: Conducted across 13 centres, this prospective, observational, non-interventional study involved 73 adults with physician confirmed SEA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!